BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 23929318)

  • 1. Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.
    Sondhi V; Patnaik SK
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):493-9. PubMed ID: 23929318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region.
    Sadykov RR; Podmelle F; Sadykov RA; Kasimova KR; Metellmann HR
    Int J Oral Maxillofac Surg; 2013 Jul; 42(7):863-7. PubMed ID: 23618833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propranolol therapy for infantile hemangioma: our experience.
    Zhang L; Wu HW; Yuan W; Zheng JW
    Drug Des Devel Ther; 2017; 11():1401-1408. PubMed ID: 28507428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propranolol for infantile hemangiomas.
    Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
    Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers.
    Celik A; Tiryaki S; Musayev A; Kismali E; Levent E; Ergun O
    J Drugs Dermatol; 2012 Jul; 11(7):808-11. PubMed ID: 22777220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes.
    Park M; Jung HL; Shim YJ; Kim HS; Yoon HS; Park SK; Cheuh HW; Lee MJ; Lee JM; Park ES; Lee JH; Lim YJ; Choi YB
    Pediatr Res; 2020 Nov; 88(5):749-755. PubMed ID: 32311699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of propranolol in the treatment of infantile hemangioma.
    Laranjo S; Costa G; Paramés F; Freitas I; Martins JD; Trigo C; Pinto FF
    Rev Port Cardiol; 2014 May; 33(5):289-95. PubMed ID: 24906291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of propranolol for complicated infantile hemangiomas.
    Vercellino N; Romanini MV; Pelegrini M; Rimini A; Occella C; Dalmonte P
    Int J Dermatol; 2013 Sep; 52(9):1140-6. PubMed ID: 23829783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral propranolol: an effective, safe treatment for infantile hemangiomas.
    Zaher H; Rasheed H; Hegazy RA; Hegazy RA; Abdelhalim DM; Gawdat HI
    Eur J Dermatol; 2011; 21(4):558-63. PubMed ID: 21697036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience.
    El Hachem M; Gesualdo F; Diociaiuti A; Berti I; Vercellino N; Boccaletti V; Neri I; Porcedda G; Greco A; Carnevale C; Oranges T; Cutrone M; Dalmonte P
    Ital J Pediatr; 2017 Apr; 43(1):40. PubMed ID: 28424095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical propranolol for treatment of superficial infantile hemangiomas.
    Xu G; Lv R; Zhao Z; Huo R
    J Am Acad Dermatol; 2012 Dec; 67(6):1210-3. PubMed ID: 22516113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propranolol for infantile haemangioma: striking effect in the first weeks.
    Katona G; Csákányi Z; Gács E; Szalai Z; Ráth G; Gerlinger I
    Int J Pediatr Otorhinolaryngol; 2012 Dec; 76(12):1746-50. PubMed ID: 22944359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late rebound of infantile hemangioma after cessation of oral propranolol.
    Shehata N; Powell J; Dubois J; Hatami A; Rousseau E; Ondrejchak S; McCuaig C
    Pediatr Dermatol; 2013; 30(5):587-91. PubMed ID: 24016283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial.
    Zaher H; Rasheed H; Esmat S; Hegazy RA; Gawdat HI; Hegazy RA; El-Komy M; Abdelhalim DM
    Eur J Dermatol; 2013; 23(5):646-52. PubMed ID: 24135427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
    Bauman NM; McCarter RJ; Guzzetta PC; Shin JJ; Oh AK; Preciado DA; He J; Greene EA; Puttgen KB
    JAMA Otolaryngol Head Neck Surg; 2014 Apr; 140(4):323-30. PubMed ID: 24526257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of superficial infantile hemangiomas with topical propranolol].
    Niu JN; Xu GQ; Lü RR; Huo R
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2013 Mar; 29(2):100-3. PubMed ID: 23772486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase.
    Vivas-Colmenares GV; Bernabeu-Wittel J; Alonso-Arroyo V; Matute de Cardenas JA; Fernandez-Pineda I
    Pediatr Dermatol; 2015; 32(3):348-52. PubMed ID: 25721095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
    Sagi L; Zvulunov A; Lapidoth M; Ben Amitai D
    Dermatology; 2014; 228(2):136-44. PubMed ID: 24556822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety].
    Qin ZP; Liu XJ; Li KL; Zhou Q; Yang XJ; Zheng JW
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(44):3130-4. PubMed ID: 20193276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth characteristics of infantile hemangiomas: implications for management.
    Chang LC; Haggstrom AN; Drolet BA; Baselga E; Chamlin SL; Garzon MC; Horii KA; Lucky AW; Mancini AJ; Metry DW; Nopper AJ; Frieden IJ;
    Pediatrics; 2008 Aug; 122(2):360-7. PubMed ID: 18676554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.